Skip to main content
Publications
Grivas P, Barata P, Moon H, Gupta S, Hutson T, Sternberg C, Brown J, Dave V, Downey C, Shillington A, Katzenstein H, Kirker M, Hanson S, Liu F, Morris V, Bhanegaonkar A, Sonpavde G. Avelumab first-line maintenance (1LM) therapy for locally advanced/metastatic urothelial carcinoma (la/mUC): results from the realworld US PATRIOT-II study. Poster presented at the Academy of Managed Care Pharmacy (AMCP) 2024; April 15, 2024. New Orleans, LA. [abstract] J Manag Care Spec Pharm. 2024 Apr; 30(4-a):S123.
Hageman SH, Petitjean C, Pennells L, Kaptoge S, Pajouheshnia R, Tillmann T, Blaha MJ, McClelland RL, Matsushita K, Nambi V, Klungel OH, Souverein PC, van der Schouw YT, Verschuren WM, Lehmann N, Erbel R, Jockel KH, Di Angelantonio E, Visseren FL, Dorresteijn JA. Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2. Eur J Prev Cardiol. 2023 Oct 26;30(15):1705-14. doi: 10.1093/eurjpc/zwad187
Pluard T, Sandin R, Parikh R, Ward M, Stansfield L, Nham T, Esterberg L, Cha-Silva A, Shah B. Health care resource utilization and cost comparison among palbociclib, abemaciclib, and ribociclib in US patients with HR+/HER2− metastatic breast cancer. Poster presented at the AMCP Nexus 2023; October 17, 2023. Orlando, FL. [abstract] J Manag Care Spec Pharm. 2023 Oct; 29(10-a Suppl):S17-8. doi: 10.18553/jmcp.2023.29.10-a.s1
Carrico J, Jia X, Zhao Y, Zhang J, Brodtkorb T, Mendelsohn A, Wu J, Feldman S, Armstrong A. Cost-effectiveness and budget impact of tildrakizumab for the treatment of moderate to severe plaque psoriasis using 2019 drug costs. Poster presented at the 2019 AMCP NEXUS; October 29, 2019. National Harbor, MD. [abstract] J Manag Care Spec Pharm. 2019 Oct; 25(10-a Suppl):S79. doi: 10.18553/jmcp.2019.25.10-a.s1
Wheeler A, Ling W, Nadipelli V, Ronquest N, Aldridge A, Solem C, Peiper N, Learned S, Heidbreder C. Recovery from opioid use disorder post-monthly buprenorphine extended release treatment: 12-month longitudinal outcomes. Poster presented at the 2019 AMCP NEXUS; October 29, 2019. National Harbor, MD. [abstract] J Manag Care Spec Pharm. 2019 Oct; 25(10-a):S14. doi: 10.18553/jmcp.2019.25.10-a.s1
Patterson BJ, Herring W, van Oorschot D, Curran D, Carrico J, Zhang Y, Ackerson BK, Bruxvoort K, Sy L, Tseng H. Public health and economic impact of adjuvanted recombinant zoster vaccine adoption for a large, integrated delivery network: utilizing real‐world epidemiological data in a budget impact model. Poster presented at the 2019 AMCP NEXUS; October 29, 2019. National Harbor, DC. [abstract] J Manag Care Spec Pharm. 2019 Oct; 25(10-a):S23.
Maurer M, Houghton K, Costa C, Dabove F, Ensina LF, Gimenez-Arnau A, Guillet G, Konstantinou GN, Labrador-Horrillo M, Lapeere H, Meshkova R, Pastorello E, Velasquez-Lopera M, Tamayo Quijano LM, Vestergaard C, Chapman-Rothe N. Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study. World Allergy Organ J. 2018 Nov 16;11(32). doi: 10.1186/s40413-018-0216-1
Patterson B, Curran D, Buck P, Varghese L, Oorschot D, Carrico J, Hicks K, Lee B, Yawn B. Cost-effectiveness of candidate adjuvanted subunit vaccine for revaccinating U.S. adults previously vaccinated against herpes zoster. Poster presented at the 2017 AMCP NEXUS; October 18, 2017. Dallas, TX. [abstract] J Manag Care Spec Pharm. 2017 Oct; 23(10-a):S20.
Ferreira-Gonzalez I, Pinar-Sopena J, Ribera A, Marsal JR, Cascant P, Gonzalez-Alujas T, Evangelista A, Brotons C, Moral I, Permanyer-Miralda G, Garcia-Dorado D, Tornos P. Prevalence of calcific aortic valve disease in the elderly and associated risk factors: a population-based study in a Mediterranean area. Eur J Prev Cardiol. 2013 Dec;20(6):1022-30. doi: 10.1177/2047487312451238
